changing from semaglutide to tirzepatide Switching Tirzepatide: A Provider's Guide Switching Semaglutide to Tirzepatide |

Although there are many modeling methods for NASH, the ob/ob-GAN NASH model is similar to human NASH characteristics of obesity and prominent liver fibrosis

IV supplements in particular carry risk of infection and contamination

Jumping across platforms while hearing the familiar background music looping quietly in the distance

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

The British Obesity and Metabolic Surgery Society (BOMSS) and the UK Specialist Pharmacy Service (SPS) both provide practical guidance on medicines management following bariatric procedures, and clinicians are encouraged to consult these resources